Review
doi: 10.3233/CBM-2011-0175.
Molecular pathology and biomarkers of bladder cancer
Affiliations
- PMID: 22112475
- DOI: 10.3233/CBM-2011-0175
Item in Clipboard
Review
Molecular pathology and biomarkers of bladder cancer
Cancer Biomark.
2010.
Free article
Abstract
Bladder cancer originates in the epithelial lining of the bladder's mucosa and develops in association with several habitual, industrial, and environmental risk factors via papillary and non-papillary pathways. In this chapter we review novel concepts concerning the molecular mechanisms of early field change in bladder neoplasia stemming from whole-organ genomic mapping studies. These mechanisms are discussed in the context of molecular pathogenesis of bladder cancer and in relation to treatment and biomarker-based detection strategies.
Similar articles
-
The origins of bladder cancer.Lab Invest. 2008 Jul;88(7):686-93. doi: 10.1038/labinvest.2008.48. Epub 2008 May 12. Lab Invest. 2008. PMID: 18475256
-
Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.Hematol Oncol Clin North Am. 2015 Apr;29(2):377-94, x-xi. doi: 10.1016/j.hoc.2014.11.003. Hematol Oncol Clin North Am. 2015. PMID: 25836941 Review.
-
Emerging Bladder Cancer Biomarkers and Targets of Therapy.Urol Clin North Am. 2016 Feb;43(1):63-76. doi: 10.1016/j.ucl.2015.08.006. Urol Clin North Am. 2016. PMID: 26614029 Review.
-
Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.Biomed Pharmacother. 2019 Dec;120:109433. doi: 10.1016/j.biopha.2019.109433. Epub 2019 Sep 27. Biomed Pharmacother. 2019. PMID: 31568988
-
Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.Expert Rev Anticancer Ther. 2008 Jul;8(7):1103-10. doi: 10.1586/14737140.8.7.1103. Expert Rev Anticancer Ther. 2008. PMID: 18588455 Review.
Cited by
-
Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases.Arch Pathol Lab Med. 2013 Oct;137(10):1337-41. doi: 10.5858/arpa.2012-0322-OA. Arch Pathol Lab Med. 2013. PMID: 24079760 Free PMC article.
-
Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.Cell Rep. 2024 May 28;43(5):114146. doi: 10.1016/j.celrep.2024.114146. Epub 2024 Apr 25. Cell Rep. 2024. PMID: 38676926 Free PMC article.
-
The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.Mol Biol Rep. 2013 Jun;40(6):4109-14. doi: 10.1007/s11033-013-2512-8. Epub 2013 May 3. Mol Biol Rep. 2013. PMID: 23640097
-
Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.Eur Urol Focus. 2019 Jul;5(4):664-675. doi: 10.1016/j.euf.2018.01.017. Epub 2018 Feb 7. Eur Urol Focus. 2019. PMID: 29428551 Free PMC article.
-
Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.Cancers (Basel). 2022 May 24;14(11):2578. doi: 10.3390/cancers14112578. Cancers (Basel). 2022. PMID: 35681556 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
